Tag: Ambarella

Finance

Eye Catching Stocks: Ambarella (NASDAQ:AMBA), EMCORE (NASDAQ:EMKR), TheStreet (NASDAQ:TST), Integrated Electrical Services, Inc. (NASDAQ:IESC), Engility Holdings, Inc. (NYSE:EGL)

Ambarella (NASDAQ:AMBA) EVP Didier Legall unloaded 15,000 shares of Ambarella stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $29.01, for a total value of $435,150.00. Ambarella, Inc. (NASDAQ:AMBA) belongs to Technology sector. Its net profit margin is 18.80% and weekly performance is 9.23%. On last trading day company shares ended up $31.83. Ambarella, Inc. (NASDAQ:AMBA) distance from … Continue reading Eye Catching Stocks: Ambarella (NASDAQ:AMBA), EMCORE (NASDAQ:EMKR), TheStreet (NASDAQ:TST), Integrated Electrical Services, Inc. (NASDAQ:IESC), Engility Holdings, Inc. (NYSE:EGL)

Colin Pettis
Finance

NASDAQ Bearish Stocks: CytRx Corporation (NASDAQ:CYTR), Alaska Communications Systems (NASDAQ:ALSK), VimpelCom (NASDAQ:VIP), Ambarella Inc (NASDAQ:AMBA)

CytRx Corporation (NASDAQ:CYTR) on Mar. 5 reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) stock performance was -6.17% in last session and finished the day at $5.32. Traded volume was 3,186,360 million shares in the last session and the average volume of the … Continue reading NASDAQ Bearish Stocks: CytRx Corporation (NASDAQ:CYTR), Alaska Communications Systems (NASDAQ:ALSK), VimpelCom (NASDAQ:VIP), Ambarella Inc (NASDAQ:AMBA)

John Bellich
Stock Movers

BioTech After Hours Active Stocks: Regeneron (NASDAQ:REGN), Ambarella (NASDAQ:AMBA), Progress Software (NASDAQ:PRGS)

In a note issued Friday, Piper Jaffray said the weakness in Regeneron (NASDAQ:REGN) is a buying opportunity, as the firm sees risks to the company’s alirocumab Phase III program as overblown, with neither Regeneron  (NASDAQ:REGN) or its development partner Sanofi (SNY) having seen any neurocognitive adverse events with the drug. The firm reiterates a Buy rating and $376 price target on shares. Deutsche Bank reports Regeneron … Continue reading BioTech After Hours Active Stocks: Regeneron (NASDAQ:REGN), Ambarella (NASDAQ:AMBA), Progress Software (NASDAQ:PRGS)

Mark Doerr